DUBLIN, Nov. 5, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its third quarter 2019 financial results including GAAP net revenues of $4.05 billion, a 3.6 percent increase from the prior year quarter. THIRD QUARTER 2019 FINANCIAL RESULTS   Executive Commentary "The third quarter 2019 results demonstrate our commitment to continued strong operational performance. The core business has grown and has been bolstered by significant pipeline progress, with three new molecular entities currently under regulatory review," said Brent Saunders, Chairman and CEO of Allergan. "VRAYLAR^®, BOTOX^® Cosmetic, JUVÉDERM^®, BOTOX^® Therapeutic, OZURDEX^® and Lo LOESTRIN^® continue to lead the way, with VRAYLAR^® growing 70 percent and U.S. BOTOX^® Cosmetic growing 10 percent in the third quarter from the prior year."

DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), today announced that its subsidiaries, Forest Laboratories, LLC, Forest Laboratories, Inc. and Forest Laboratories Holdings Ltd. (collectively "Forest") have reached a resolution with a plaintiff class of direct purchasers of Namenda, concluding the previously disclosed direct purchaser class action litigation in the U.S. District Court for the Southern District of New York. The settlement makes no admission of wrongdoing on the part of the company and resolves the litigation that was scheduled to go to trial in October 2019.  

DUBLIN, Oct. 25, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the fourth quarter of 2019. The dividend will be paid on December 13, 2019 to shareholders of record at the close of business on November 13, 2019.

DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX^® for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP). This marks the 11^th BOTOX^® therapeutic indication, having been approved for pediatric upper limb spasticity (ULS) earlier this year. Spasticity is a debilitating neurological condition involving muscle stiffness that can result in tight muscles in the upper and lower limbs, and can interfere with movement. The severity can range from mild to severe muscle stiffness. 

DUBLIN, Oct. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago, IL October 24-27 2019. The meeting will be held at the Hyatt Regency Chicago and the scheduled times (noted in local Central Time) for the Allergan presentations are as follows:

DUBLIN, Oct. 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release third quarter 2019 financial results on Tuesday, November 5, 2019, prior to the open of U.S. financial markets. For additional materials related to Allergan's third quarter results, please visit Allergan's Investor Relations website at https://www.allergan.com/investors/events-presentations.

DUBLIN, Oct. 14, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) (the "Company" or "Allergan") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie Inc ("AbbVie"). As described below, more than 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the "Court Meeting") and at an extraordinary general meeting of shareholders (the "EGM") were in favor of the transaction, representing (in each case) approximately 68.6 percent of the shares outstanding and eligible to be voted at each of the Allergan shareholder meetings held on October 14, 2019 in Dublin, Ireland.

DUBLIN, Oct. 11, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced two-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with neovascular (wet) age-related macular degeneration (nAMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab. These data were presented as a late-breaking oral presentation during Retina Subspecialty Day at the Annual Meeting of the American Academy of Ophthalmology (AAO).

DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma. The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment regimen that fits their lifestyle. The resources available on www.MyGlaucoma.com are supported by a new survey of patients living with glaucoma and eye doctors, conducted in collaboration with Glaucoma Research Foundation (GRF), that found more than 75 percent of patients worry about vision loss because of the disease, but nearly half consider glaucoma to be only somewhat or not serious. In fact, research published by the American Journal of Ophthalmology suggests that 27 percent of patients with glaucoma are estimated to go blind in one eye over a 10-year period.

DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in eye care, today announced the launch of three new over-the-counter (OTC)  REFRESH^® RELIEVA™ products: REFRESH^® RELIEVA™, REFRESH^® RELIEVA™ PF (preservative-free) multidose, and REFRESH^® RELIEVA™ FOR CONTACTS. This new line of artificial tear formulations available in preserved, preservative-free multidose, and a formula designed for contact lens wearers, are specially formulated to relieve discomfort due to eye dryness and to prevent further irritation.  REFRESH^®, a doctor recommended brand of artificial tears, continues to expand its portfolio by offering the only family of products in the U.S. with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), glycerin, and HydroCell™ technology--Allergan's proprietary sodium chloride (NaCl) free, glycerin-based solution that enables hydration and maintains the volume of cells on the ocular surface.